2025
Breastfeeding after breast cancer in young BRCA carriers
Blondeaux E, Delucchi V, Mariamidze E, Bernstein-Molho R, Frank S, Ferrari A, Linn S, Kim H, Agostinetto E, Paluch-Shimon S, Cortesi L, Di Meglio A, Balmana J, Yerushalmi R, Rodriguez-Wallberg K, Renaud T, Cui W, Moore H, Wong S, Pogoda K, Lustberg M, Phillips K, Han S, Puglisi F, Vernieri C, Bajpai J, Sonnenblick A, Rousset-Jablonski C, De Marchis L, De Giorgi U, Bianchini G, Texeira L, Duhoux F, Villarreal-Garza C, Sini V, Fruscio R, Del Mastro L, Demeestere I, Azim H, Peccatori F, Partridge A, Lambertini M. Breastfeeding after breast cancer in young BRCA carriers. Journal Of The National Cancer Institute 2025, djaf177. PMID: 40623009, DOI: 10.1093/jnci/djaf177.Peer-Reviewed Original ResearchContralateral breast cancerBreast cancer diagnosisDisease-free survivalBRCA carriersLocoregional recurrenceBilateral risk-reducing mastectomyBreast cancerOverall survivalCancer diagnosisStage I-III invasive breast cancerRisk-reducing mastectomyBreastfeeding groupCumulative incidenceCumulative incidence of locoregional recurrenceIncidence of locoregional recurrenceInvasive breast cancerRetrospective cohort studySafety of breastfeedingHospital-basedBreastfeeding statusCohort studySmoking habitsBreastfeedingGermline BRCAMedian follow
2024
Clinical utility of upfront liquid biopsy in non-small cell lung cancer in the community setting.
Doro L, Ozcan G, Vredenburgh J, Collier E. Clinical utility of upfront liquid biopsy in non-small cell lung cancer in the community setting. Journal Of Clinical Oncology 2024, 20: 316-316. DOI: 10.1200/op.2024.20.10_suppl.316.Peer-Reviewed Original ResearchNon-small cell lung cancerNon-small cell lung cancer patientsCell lung cancerLiquid biopsyAdvanced non-small cell lung cancerLung cancerDiagnosis of advanced non-small cell lung cancerDiagnosed NSCLCNext generation sequencingMolecular profilingClinical utilityLiquid biopsy resultsComprehensive molecular profilingTarget genetic abnormalitiesKRAS G12C mutationProportion of patientsProgression of eGFRPartial responsePlasma genotypingBiopsy resultsBRCA carriersTreatment failureOncoKB databaseSystemic treatmentActionable mutations
2017
Radiation Oncology Considerations in the Management of Mutation Carriers with Breast Cancer
Moran M. Radiation Oncology Considerations in the Management of Mutation Carriers with Breast Cancer. 2017, 151-170. DOI: 10.1007/978-3-319-59198-8_9.Peer-Reviewed Original ResearchBreast cancerMutation carriersRadiation therapyLocal-regional managementPost-mastectomy settingBreast conservation therapyBRCA mutation carriersTreatment management decisionsBRCA mutation statusHereditary breast cancerBreast conservationTNBC patientsConservation therapyBRCA carriersFamily historyMutation statusRadiation therapy deliveryTreatment conceptGenetic testingBRCA genesCancerTherapyStrong associationTherapy deliveryPresent guidelines
2015
Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status
Kotsopoulos J, Rosen B, Fan I, Moody J, McLaughlin JR, Risch H, May T, Sun P, Narod SA. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status. Gynecologic Oncology 2015, 140: 42-47. PMID: 26556769, DOI: 10.1016/j.ygyno.2015.11.009.Peer-Reviewed Original ResearchConceptsBRCA mutation statusLong-term survivalEpithelial ovarian cancerResidual diseaseOvarian cancerMutation carriersMutation statusOntario Cancer RegistryTreatment-related factorsTen-year survivalBRCA2 mutation carriersBRCA1 mutation carriersMajority of womenInitial survival advantageActuarial survivalMortality benefitSerous cancerCancer RegistryBRCA carriersBRCA mutationsMedical recordsBRCA2 mutationsSurvival statusSurvival advantageClinical information
2012
Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
Bolton K, Trench G, Goh C, Sadetzki S, Ramus S, Karlan B, Lambrechts D, Despierre E, Barrowdale D, McGuffog L, Healey S, Easton D, Sinilnikova O, Benítez J, García M, Neuhausen S, Gail M, Hartge P, Peock S, Frost D, Evans D, Eeles R, Godwin A, Daly M, Kwong A, K. E, Lázaro C, Blanco I, Montagna M, D'Andrea E, Nicoletto M, Johnatty S, Kjær S, Jensen A, Høgdall E, Goode E, Fridley B, Loud J, Greene M, L. P, Chetrit A, Lubin F, Hirsh-Yechezkel G, Glendon G, Andrulis I, Toland A, Senter L, Gore M, Gourley C, Michie C, Song H, Tyrer J, Whittemore A, McGuire V, Sieh W, Kristoffersson U, Olsson H, Borg Å, Levine D, Steele L, Beattie M, Chan S, Nussbaum R, Moysich K, Gross J, Cass I, Walsh C, Li A, Leuchter R, Gordon O, Garcia-Closas M, Gayther S, Chanock S, Antoniou A, Pharoah P, Investigators A. Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer. JAMA 2012, 307: 382-389. PMID: 22274685, PMCID: PMC3727895, DOI: 10.1001/jama.2012.20.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerInvasive epithelial ovarian cancerBRCA2 carriersOvarian cancerGermline mutationsOverall survivalInvasive EOCEpithelial ovarian cancer casesEffect of BRCA1BRCA2 mutation carriersSurvival of womenYear of diagnosisPathogenic germline mutationsBRCA1 carriersBRCA2 mutationsBRCA carriersFavorable survivalImprove prognosisSurvival differencesMutation carriersBRCA2Pooled analysisBRCA1Observational studyCancer
2002
Histopathologic Features of Genetically Determined Ovarian Cancer
Shaw P, McLaughlin J, Zweemer R, Narod S, Risch H, Verheijen R, Ryan A, Menko F, Kenemans P, Jacobs I. Histopathologic Features of Genetically Determined Ovarian Cancer. International Journal Of Gynecological Pathology 2002, 21: 407-411. PMID: 12352190, DOI: 10.1097/00004347-200210000-00011.Peer-Reviewed Original ResearchConceptsInvasive serous carcinomasOvarian carcinomaSilverberg gradeGermline mutationsHistologic typeSerous carcinomaNuclear gradeGOG grade 3High histologic gradeBRCA1/BRCA2Serous histologyGynecologic pathologistsHistologic featuresHistopathologic featuresBRCA carriersHistologic gradeBRCA mutationsOvarian cancerArchitectural gradeBRCA2 mutationsGrade 3Germline BRCA1CarcinomaMutation statusControl group
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply